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CASE STUDY
Extremely high expression 
of serum alpha-fetoprotein level of gastric 
adenocarcinoma: a rare case with an 
unexpected well-prognosis
Weihua Gong1*†, Dawei Shou1† and Ping Gong2
Abstract 
Introduction:  Alpha-fetoprotein (AFP)-producing gastric cancer is a relatively rare form of stomach malignancy. 
Patients with higher serum AFP level (>300 ng/mL) will have a poorer prognosis.
Case description:  In this study, we present a case of 77-year-old woman with an extremely high expression of 
serum AFP level (>10,000 ng/mL) of gastric cancer. Histological examination revealed gastric adenocarcinoma (Bor-
mann III gastric tumor) invading into the serosal layer and vessel. After receiving a successful total gastrectomy with 
D2 dissection, this patient underwent chemotherapy with SOX [oxaliplatin (130 mg/m2/day) iv. at day 1 + S-1 (80 mg/
m2/day) from day 1–day 14]. The patient remains alive without disease for 29 months after surgery. Serum AFP level 
decreased to normal range.
Discussion and Evaluation: We have evaluated the level of AFP, and discussed the reason for the good prognosis for 
this patient.
Conclusions: The good prognosis may be related with her early stage (N0 and without liver metastasis) and radical 
surgery.
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Background
Alpha fetoprotein (AFP) is an oncofetal glycoprotein 
mainly produced in the liver, yolk sac and gastrointesti-
nal tract during fetal period (Gitlin et al. 1972). Although 
serum AFP level is apparently low in adults, it may sig-
nificantly increase in the pathological conditions including 
yolk sac tumors, hepatocellular carcinoma, and cirrhosis 
and hepatitis (Purves et  al. 1970). However, some other 
diseases can also be related with elevated levels of AFP, 
gastric cancer included. Gastric cancer is the fourth com-
mon cancer and the second common cause of cancer 
death worldwide (Sun et al. 2015). AFP-producing gastric 
cancer(AFPGC) is a relatively rare aggressive malignancy 
and its incidence is around 3% among all gastric cancers, 
which is reported by Bourrille et  al. (1970) for the first 
time (Kono et al. 2002). Indeed, most AFP-producing GC 
patients can not survive for more than 1  year (Inagawa 
et al. 2001). In this present paper, we describe a rare case 
of an old woman suffering from gastric cancer with an 
extremely high expression of serum AFP level (>10,000 ng/
mL). After receiving a successful total gastrectomy with 
D2 dissection and chemotherapy, this patient remains 
alive for 29 months. Serum AFP level of the patient strik-
ingly decreased to 0.7  ng/mL without a rebound. To the 
best of our knowledge, this is the first successful case with 
extremely high expression of pre-operative serum AFP 
level and an unexpected good prognosis.
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Case report
A 77-year-old woman presented to the surgery depart-
ment with complaints of 1-month history of upper 
abdominal pain and dizziness. She denied fevers, change 
in the color of the urine or stool, nausea or vomit-
ing. Physical exam revealed Anemic conjunctiva but no 
enlarged lymph nodes such as Virchow lymph nodes. In 
laboratory tests, occult blood test of stool showed posi-
tive. Hematological test revealed anemia, as evidenced 
by a low level of hemoglobin (Hb), 4.4 g/dL. The serum 
level of AFP was remarkably elevated (>10,000  ng/mL), 
whereas the level of carbohydrate antigen 19-9 (CA19-9) 
and carcinoembryonic antigen (CEA) were within nor-
mal range.
Endoscopic examination revealed a protruding lesion 
(about 0.3 * 0.3 cm) in the inferior wall of corpus, patchy 
congestion of mucosa in the lesser curvature of corpus, 
and deep depression. It occupied the lumen about a quar-
ter perimeter with infiltrated mucosa in the anterior wall 
of antrum. Gastric biopsy exhibited moderately differen-
tiated adenocarcinoma (Fig.  1). To further evaluate the 
feature of the tumor and its surroundings, subsequent 
abdominal computed tomography (CT) scans were per-
formed. The images manifested the thickened gastric 
antrum and the swelled lymph nodes surrounding the 
stomach (Fig. 2).
The patient was clinically diagnosed as AFP-producing 
gastric cancer. Afterwards, total gastrectomy with D2 
lymph node dissection was performed. No liver or dis-
tant metastasis was observed. The resected specimen dis-
played that this tumor invaded into the serosal layer of 
gastric wall and vessel. Immunohistochemistry staining 
(IHC) showed AFP+++, hepatocyte−, CD34−, CD10−, 
CK8+++, CK18+++, CK19+++, CK20−, CK7−, P53 
++, and Ki67 50–60%. No metastasis of lymph nodes 
was found around the stomach.
Postoperatively, The patient successfully received six 
courses of SOX chemotherapy [oxaliplatin (130  mg/m2/
day) iv. at day 1 + S-1 (80 mg/m2/day) from day day 1–
day 14). Afterwards, a careful follow-up was made on the 
patient. Abdominal CT scan was made every 6  months 
(Fig.  3) and there is no evidence for recurrence or liver 
metastasis found. Test of tumor biomarkers was per-
formed to monitor alteration of serum AFP level (Fig. 4). 
The patient has survived for 29 months and remains alive 
by far.
Discussion
Since the first report of AFP-producing gastric cancer 
in 1970, AFP-producing gastric cancer has been clas-
sified into four histological subtypes: hepatoid, yolk sac 
tumor, enteroblastic and common adenocarcinoma 
type (Bourreille et  al. 1970; Kinjo et  al. 2012). Hepatoid 
adenocarcinoma of the stomach was reported by Ishi-
kura et al. (1985) for the first time. The diagnosis of this 
type depends on morphology of hepatic differentiation, 
regardless of serum AFP levels (Nagai et al. 1993). Kinjo 
et  al. (2012) suggest that AFPGC develops as common 
adenocarcinoma and enteroblastic type in the mucosa, 
and then differentiate into enteroblastic and hepatoid 
adenocarcinoma type. In this case, since no specific mor-
phology was observed, we made the diagnosis of AFP-
producing gastric cancer.
AFP-producing gastric cancer highly expresses VEGF-
C, SALL4, and c-Met/HGF (Amemiya et al. 2000; Kamei 
et  al. 2003; Ushiku et  al. 2010). VEGF-C facilitates for-
mation of rich neovascularization, and SALL4 maintains 
Fig. 1 Haematoxylin and eosin staining for alpha-fetoprotein (AFP)-
producing gastric adenocarcinoma. AFPGC cell (white arrow)
Fig. 2 Computed tomography (CT) imaging of the abdomen before 
surgery showing a local thickened gastric wall in a 77-year-old 
woman. Thickening of the gastric antrum (white arrow)
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self-renewal and pluripotent properties of embryonic 
stem cells (Kamei et al. 2003; Ushiku et al. 2010). In the 
immunohistochemistry staining, Ki67 labeling index is 
significantly higher in the AFP-producing gastric cancers 
than in the AFP-negative gastric cancers. Ki67 is related 
with cell proliferation and tumor progression (Koide et al. 
1999). Compared with AFP-negative gastric cancer, AFP-
producing gastric cancer possesses higher proliferative 
activity, weaker apoptosis and richer neovascularization. 
In this case, Ki67 index is high, while the prognosis of the 
patient is well. IHC result is important but not the most 
significant factor determining the outcome of AFPGC.
The treatment of AFP-producing gastric cancer mainly 
includes radical surgery and chemotherapy. Radical sur-
gery is of significance for AFPGC. Xie et al. (2015) have 
emphasized that R0 resection is the most important cura-
tive method. And there is a report that no significant dif-
ference of the prognosis exists between the AFP-positive 
group and the AFP-negative group after radical surgery 
(Nagai et al. 1993). The choice for chemotherapy is vari-
able. Preoperative FLEP chemotherapy [a combination 
of chemotherapy with 5-fluorouracil (5-FU), leucovorin 
(LV), etoposide (VP-16) and Cis-diamminedichloroplat-
inum (CDDP)] was reported to improve the prognosis 
of AFP-producing GC owing to down-staging of cancer. 
A better response rate (70%) was observed among stage 
IV AFP-producing patients (Kochi et  al. 2004). Combi-
nation of 5-FU and paclitaxel or combination of gemcit-
abine and cisplatin were also reported to show moderate 
efficacy (De Lange et  al. 2004; Takeyama et  al. 2007). 
Fig. 3 Abdominal computed tomography scans 6- (a), 12- (b), 18- (c), and 24- (d) months after surgical therapy. The scans do not exhibit any recur-
rence of the tumor or metastatic lymph nodes
Fig. 4 Serial alterations in serum alpha-fetoprotein (AFP) concentra-
tions in a 77-year-old woman without recurrent AFP-producing gas-
tric cancer during the entire 29-month post-operative course by far
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Platinum is received by a large amount patients (Baek 
et  al. 2011). In this case, R1 section and chemotherapy 
with SOX (oxaliplatin + S-1) was given.
The prognosis of AFP-producing gastric cancer is usu-
ally poor, which is due to advanced stage, liver metastasis 
(Kono et  al. 2002; Shibata et  al. 2007). The incidence of 
synchronous and metachronous liver metastasis is high 
in AFPGC patients (Hirajima et  al. 2013; Inoue et  al. 
2010). Liver metastasis, can significantly affect the 5-year 
survival rate between patients with and without liver 
metastasis, which has been taken into account for the 
only independent prognostic factor (Hirajima et al. 2013). 
And if the patient is without lymph node and liver metas-
tasis, they could always be cured (Xie et al. 2015). Apart 
from lymph node and liver metastasis, the level of serum 
AFP was reported to be associated with the poor prog-
nosis despite no positive correlation. A significant poorer 
1-, 3-, and 5-year survival was observed when serum AFP 
was >300 ng/mL (Lin et al. 2014). Despite the aggressive 
biological behavior of AFPGC, the proper treatment is a 
significant factor for the prognosis of AFPGC. Xie et al. 
(2015) proposed that R0 resection is of significance for 
the prognosis of AFPGC. In this case, the patient did not 
have lymph node and liver metastasis, though with high 
level of serum AFP, and R1 resection was performed fol-
lowed by SOX chemotherapy. This may partly account for 
the good prognosis.
In addition, it is not well defined that alteration of pre-
operative serum AFP level or post-operative serum AFP 
level can be utilized for predicting and monitoring gastric 
cancer recurrence (Inoue et  al. 2010). Choi et  al. (2006) 
reported that the serum AFP level at the time of initial 
diagnosis rather than at the time-point of tumor recur-
rence is strongly associated with subsequent recurrence 
event. In our present study, the initial level of serum AFP 
level was extremely high (>10,000 ng/mL) (Fig. 4). But this 
patient did not manifest tumor recurrence. Therefore, a 
large-scale research data is required for further investiga-
tion. Furthermore, owing to the limited amount of AFP-
producing patients, it is difficult to sub-stratify them and 
make a comparison of prognosis among various patholog-
ical types. To date, no literature addressed this issue.
Taken together, AFP-producing gastric cancer is a rare 
type of gastric cancer, with an incidence of 3% among all 
gastric cancers. And AFP-producing gastric caner is not 
totally equal to hepatoid adenocarcinoma of the stomach. 
Though the prognosis of AFPGC is usually quite poor, it 
may be cured if the patient is in the early stage and R0 
resection and chemotherapy are given. Early detection 
seems very important for those patients.
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